Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Comparative Evaluation of Multiparametric Magnetic Resonance Imaging and Micro-Ultrasound for the Detection of Clinically Significant Prostate Cancer in Patients with Prior Negative Biopsies.
Beatrici E, Frego N, Chiarelli G, Sordelli F, Mancon S, Saitta C, De Carne F, Garofano G, Arena P, Avolio PP, Gobbo A, Uleri A, Contieri R, Paciotti M, Lazzeri M, Hurle R, Casale P, Buffi NM, Lughezzani G. Beatrici E, et al. Among authors: gobbo a. Diagnostics (Basel). 2024 Mar 1;14(5):525. doi: 10.3390/diagnostics14050525. Diagnostics (Basel). 2024. PMID: 38472997 Free PMC article.
Clinical and pathological predictors of persistent T1 HG at second resection.
Gobbo A, Fasulo V, Contieri R, Uleri A, Avolio PP, Frego N, Lughezzani G, Saitta C, Taverna G, Zanoni M, Mancon S, Colombo P, Valeri M, Saita A, Lazzeri M, Buffi NM, Hurle R, Casale P. Gobbo A, et al. Urologia. 2023 Aug;90(3):482-490. doi: 10.1177/03915603231181619. Epub 2023 Jun 21. Urologia. 2023. PMID: 37341094 Free PMC article.
Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective Trial.
Contieri R, Lughezzani G, Buffi NM, Taverna G, Giacobbe A, Micheli E, Barra S, Colombo P, Vanni E, Guazzoni G, Lazzeri M, Hurle R; HuNIRe Study Group. Contieri R, et al. Front Oncol. 2022 May 18;12:879399. doi: 10.3389/fonc.2022.879399. eCollection 2022. Front Oncol. 2022. PMID: 35664755 Free PMC article.
MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity.
Boulton DP, Hughes CJ, Vaira V, Del Gobbo A, Palleschi A, Locatelli M, Danis E, Raza M, Neumann AJ, Purdy SC, Lerma R, Meshki J, Ford HL, Prekeris R, Morrissey C, Caino MC. Boulton DP, et al. Among authors: del gobbo a. Cell Rep. 2024 Dec 24;44(1):115120. doi: 10.1016/j.celrep.2024.115120. Online ahead of print. Cell Rep. 2024. PMID: 39723893 Free article.
Digital transition in pathology lab: a survey from the Lombardy region.
Belloni E, Bonoldi E, Bovo G, Buoro S, Cerati M, Cribiú FM, Dainese E, Del Gobbo A, Facchetti M, Gianatti A, Gianelli U, Giunta P, L'Imperio V, Milione M, Nebuloni M, Pagni F, Paulli M, Piga A, Pasotti F. Belloni E, et al. Among authors: del gobbo a. Pathologica. 2024 Aug;116(4):232-241. doi: 10.32074/1591-951X-1004. Pathologica. 2024. PMID: 39377505 Free PMC article.
134 results